Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing

Abstract : The AdaptResponse trial is designed to test the hypothesis that preferential adaptive left ventricular-only pacing with the AdaptivCRT((R)) algorithm reduces the incidence of the combined endpoint of all-cause mortality and intervention for heart failure (HF) decompensation, compared with conventional cardiac resynchronization therapy (CRT), among patients with a CRT indication, left bundle branch block (LBBB) and normal atrioventricular (AV) conduction. The AdaptResponse study is a prospective, randomized, controlled, single-blinded, multicentre, clinical trial ( Identifier: NCT02205359), conducted at up to 200 centres worldwide. Following enrolment and baseline assessment, eligible subjects will be implanted with a CRT system containing the AdaptivCRT algorithm, and randomized in a 1:1 fashion to either a treatment (AdaptivCRT') or control (Conventional CRT') group. The study is designed to observe a primary endpoint in 1100 patients (event-driven') and approximately 3000 patients will be randomized. The primary endpoint is the composite of all-cause mortality and intervention for HF decompensation; secondary endpoints include all-cause mortality, intervention for HF decompensation, clinical composite score (CCS) at 6 months, atrial fibrillation, quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), health outcome measured by the EQ-5D instrument, all-cause readmission after a HF admission, and cost-effectiveness. The AdaptResponse clinical trial is powered to assess clinical endpoints and is expected to provide definitive evidence on the incremental utility of AdaptivCRT-enhanced CRT systems.
Complete list of metadatas

Cited literature [39 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01577962
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, June 20, 2018 - 3:28:50 PM
Last modification on : Thursday, August 22, 2019 - 2:00:04 PM
Long-term archiving on : Wednesday, September 26, 2018 - 1:13:22 AM

File

Filippatos - Rationale and des...
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Gerasimos Filippatos, David Birnie, Michael R. Gold, Bart Gerritse, Ahmad Hersi, et al.. Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. European Journal of Heart Failure, Oxford University Press (OUP), 2017, 19 (7), pp.950--957. ⟨10.1002/ejhf.895⟩. ⟨hal-01577962⟩

Share

Metrics

Record views

712

Files downloads

83